Investment Rating - The report maintains an "Accumulate" rating for the company [6][4]. Core Views - The company achieved a revenue of 1.246 billion RMB in 1H25, representing a year-over-year growth of 35.35%, with a net profit of 261 million RMB, up 72.29% year-over-year [1][2]. - The demand for AIoT remains strong, contributing to revenue growth from new markets such as 3D printing, AI toys, and medical devices [1][3]. - The company is expanding its product offerings in high-performance SoC and high-speed data transmission markets, leveraging its existing ecosystem advantages [1][4]. Summary by Sections Financial Performance - In 2Q25, the company reported a revenue of 688 million RMB, a year-over-year increase of 29.02% and a quarter-over-quarter increase of 23.28% [1]. - The gross margin improved to 46.69%, up 2.58 percentage points year-over-year, while the net margin increased to 24.52%, up 5.98 percentage points year-over-year [1][2]. Product Development - The company is actively investing in the development of Wi-Fi 7 and multi-core RISC-V technologies, with R&D expenses reaching 268 million RMB in 1H25, a year-over-year increase of 22.66% [2]. - The first Wi-Fi 6E wireless communication chip is expected to enter mass production in the second half of 2025, marking a significant advancement in the high-performance wireless communication chip sector [3]. Profit Forecast and Valuation - The report revises the gross margin forecasts for 2025, 2026, and 2027 to 44.94%, 43.10%, and 41.98%, respectively, and raises the net profit estimates for the same years to 556 million RMB, 718 million RMB, and 970 million RMB [4][10]. - The target price is set at 237.10 RMB, reflecting a 55x PE ratio for 2026, with the previous target price being 173.7 RMB [4][7].

Investment Rating - The report maintains an "Overweight" rating for the company [7] Core Views - The company's revenue for 1H25 was 2.254 billion RMB, a year-on-year decrease of 14%, with net profit attributable to shareholders at 205 million RMB, down 40% year-on-year. The second quarter saw revenue of 858 million RMB, a 17% year-on-year decline and a 39% quarter-on-quarter decline, with net profit slightly below expectations due to lower gross margins [1][5] - The company continues to emphasize a high dividend strategy, proposing a mid-term dividend of 286 million RMB, corresponding to a dividend per share (DPS) of 0.40 RMB, with a payout ratio of 140%, indicating strong value [4] - The report anticipates continued pressure on pipeline and city gas margins, projecting a 14% year-on-year decline in pipeline gas gross profit for 2025 and a 28% decline for city gas gross profit, primarily due to weak demand and delayed pricing adjustments for residential gas [2][3] Summary by Sections Financial Performance - In 1H25, pipeline gas revenue decreased by 11.5% year-on-year to 1.047 billion RMB, with a gross margin of 9.1%, down 1.1 percentage points year-on-year. The city gas segment saw an 8.7% year-on-year revenue decline to 915 million RMB, with a gross margin of 9.8%, down 4.8 percentage points year-on-year [2][3] Dividend Policy - The company plans to distribute a mid-term dividend of 286 million RMB, reflecting a 10% decrease year-on-year, with a payout ratio significantly higher than the previous year's 93% [4] Profit Forecast Adjustments - The report revises the profit forecast for 2025-2027, reducing net profit estimates by 18% for 2025, 19% for 2026, and 18% for 2027, leading to an expected EPS of 0.63 RMB for 2025 [5][24] Valuation - The target price is adjusted to 10.63 RMB, down from 12.16 RMB, based on a 17x PE for 2025, while the current dividend yield of 8.1% is significantly higher than the industry average of 4.0% [5][25]

证券研究报告 云南白药 (000538 CH) 工业收入双位数增长 工业收入双位数增长，气雾剂、气血康表现亮眼 1H25 工业收入 85.0 亿元（+11% yoy），毛利率 67.9%（+0.6pct yoy）， 我们预计全年工业收入维持双位数增长：1）药品 BG 收入 47.5 亿元（+11% yoy），白药系列表现强劲，气雾剂收入同比增 21%至 15 亿元，膏剂、胶 囊、创可贴、散剂收入均同比显著增长，特色品种表现亮眼，气血康收入同 比翻一倍至 2 亿元，参苓健脾胃收入超 1 亿元，蒲地蓝收入约 1 亿元；2） 健康品 BG 收入 34.4 亿元（+9% yoy），云南白药牙膏市占率维持国内第 一，养元青收入同比增长 11%至 2.2 亿元；3）中药资源 BG 收入 9.14 亿元 （+6.3% yoy）。 经营指标稳健 公司公告 1H25 收入、归母净利、扣非归母 212.6、36.3、34.6 亿元（+4%、 +14%、+10% yoy），其中 2Q25 收入、归母净利、扣非归母 104.2、17.0、 15.7 亿元（+8%、+14%、+9% yoy）。公司公告特别分红方案，计划每 10 股派现 ...

证券研究报告 澳博控股 (880 HK) 港股通 份额/EBITDA Margin 下滑，下调至持有 2025 年 9 月 02 日│中国香港 博彩 | 华泰研究 | | 中报点评 | 投资评级(下调): | 持有 | | --- | --- | --- | --- | --- | | 2025 年 | 9 月 02 日│中国香港 | 博彩 | 目标价(港币): | 3.00 | | 何翩翩 | 研究员 | | --- | --- | | SAC No. S0570523020002 | purdyho@htsc.com | | SFC No. ASI353 | +(852) 3658 6000 | 易楚妍* 联系人 SAC No. S0570124070123 yichuyan@htsc.com +(86) 21 2897 2228 基本数据 | 目标价 (港币) | 3.00 | | --- | --- | | 收盘价 (港币 截至 9 月 1 日) | 2.92 | | 市值 (港币百万) | 20,737 | | 6 个月平均日成交额 (港币百万) | 57.87 | | 52 周价格范围 (港币) ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 46.32 [7][5]. Core Views - The company is entering a new development phase with stable cash flow from existing products and new growth from innovative drugs. The collaboration with Pfizer for drug 707 is progressing well, enhancing overseas clinical trials [1][3]. - The first payment for drug 707 is expected to be confirmed within the year, which could significantly impact the company's valuation [3]. - The company is increasing its R&D investment, with a focus on approximately 30 projects in various stages of development, indicating strong innovation potential [4]. Summary by Sections Existing Business Performance - In the first half of 2025, the company reported stable revenue performance with total revenue of CNY 43.6 billion, a slight decrease of 1% year-on-year. The breakdown includes: - Teva revenue of CNY 23.7 billion (-4% YoY) with a market share of 63% - EPO revenue of CNY 4.5 billion (-12% YoY) - Mandi revenue of CNY 6.8 billion (+24% YoY) - Sanofi revenue of CNY 6.4 billion (+7.6% YoY) [2]. R&D and Innovation - The company has increased its R&D expense ratio to 12.6% (+1.8 percentage points YoY), with R&D expenses reaching CNY 5.5 billion (+15% YoY). The pipeline includes 30 projects across various therapeutic areas, showcasing significant market potential [4]. Financial Projections - The report forecasts net profits for 2025-2027 to be CNY 10.42 billion, CNY 2.82 billion, and CNY 2.99 billion respectively, with a notable increase of 398% in 2025 [11]. - The company is valued at CNY 101.5 billion using the SOTP method, with existing business valued at CNY 22.7 billion and innovative drugs at CNY 49.6 billion [12][14].

Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 39.27 [1][5][7] Core Views - The company is a leading industrial valve manufacturer in China, focusing on the energy sector while expanding into traditional and emerging fields such as oil and gas, chemicals, power, marine engineering, shipbuilding, fine chemicals, nuclear power, hydrogen energy, energy storage, and carbon capture [1] - Despite moderate domestic demand, the company's overall profitability is expected to improve due to an increase in overseas sales and continuous breakthroughs in high-end products [1][3] - The company has achieved significant revenue growth, with a 19.96% year-on-year increase in revenue for H1 2025, reaching RMB 3.404 billion, and a 30.44% increase in net profit, amounting to RMB 637 million [2][16] Summary by Sections Financial Performance - In H1 2025, the company reported revenue of RMB 3.404 billion, a year-on-year increase of 19.96%, and a net profit of RMB 637 million, up 30.44% year-on-year [2][16] - The gross profit margin for H1 2025 was 35.76%, an increase of 0.49 percentage points year-on-year, while the overall expense ratio decreased to 12.01%, down 1.24 percentage points year-on-year [2][16] - Operating cash flow improved significantly, reaching RMB 913 million, a year-on-year increase of 1188.94% [2] Global Expansion - The company's overseas revenue for 2024 is projected to be RMB 3.813 billion, a year-on-year increase of 25.95%, with an overseas gross margin of 41.72%, up 9.95 percentage points [3] - The company is leveraging the "Belt and Road" initiative and higher levels of openness to expand its international market presence, particularly in the Asia-Pacific, Middle East, and European markets [3] High-End Product Development - The company has made significant advancements in high-end valve technology, including the development of ultra-low temperature double-eccentric butterfly valves and high-pressure fully welded ball valves [4] - The company has successfully delivered nearly a thousand valves for the international nuclear fusion ITER project and has participated in several overseas nuclear power projects [4] Profit Forecast and Valuation - The profit forecast for 2025 and 2026 has been revised upwards, with net profit estimates increased by 48.31% and 68.56% to RMB 1.435 billion and RMB 1.745 billion, respectively [5][12] - The target price has been adjusted to RMB 39.27, reflecting a price-to-earnings ratio of 21 times for 2025, indicating a premium valuation due to the company's international competitive advantages and successful high-end product expansion [5][19]

Investment Rating - The report maintains an "Overweight" rating for the banking sector [8]. Core Insights - The banking sector has shown a recovery in performance, with revenue and net profit growth of +1.0% and +0.8% year-on-year for H1 2025, respectively, indicating an improvement compared to Q1 2025 [14][29]. - Key focus areas include accelerated non-loan driven expansion, stable credit issuance, a recovery in deposits from a low base, narrowing interest margin declines leading to a recovery in net interest income, improved growth in non-interest income, and ongoing retail risk clearance [1][2][3]. Summary by Sections Market Overview - The banking sector has experienced a slight rebound with a +13.4% absolute return year-to-date as of August 29, 2025, although it slightly underperformed the broader market [13]. - The report anticipates a potential divergence in sector performance, favoring high-quality regional banks and high-dividend Hong Kong-listed banks for investment [13]. Profitability Breakdown - The net interest margin for listed banks was measured at 1.41% for H1 2025, showing a slight improvement from Q1 2025 [3][14]. - Non-interest income has seen a year-on-year increase of 10.7% in H1 2025, driven by a recovery in capital markets [3][15]. - The report highlights a need to monitor interest rate risks due to recent market volatility [3][15]. Asset and Liability Management - Total assets and liabilities for listed banks grew by +9.6% year-on-year as of H1 2025, with significant contributions from non-loan driven growth [2][16]. - The report notes a recovery in deposits, with a year-on-year increase of +8.3% in H1 2025, attributed to a low base effect from the previous year [2][17]. Risk Assessment - The non-performing loan (NPL) ratio remained stable at 1.23% as of H1 2025, with a provision coverage ratio of 238% [4][18]. - The report indicates a slight increase in retail loan NPLs, suggesting ongoing monitoring of retail credit risks [4][18]. Market Outlook - The report suggests that the narrowing of interest margin declines and reduced non-interest income volatility will support revenue and profit growth for banks in the near term [5][14]. - It emphasizes the importance of identifying quality stocks with structural opportunities in the banking sector, particularly those with strong performance and growth potential [5][14].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 140.50 [4][6]. Core Views - The company achieved revenue of RMB 222 million in 1H25, representing a year-over-year increase of 43.41%, while the net profit attributable to the parent company was a loss of RMB 104 million, showing a reduction in losses [1][2]. - The growth in revenue is attributed to the recovery of the industry cycle, ongoing support from domestic policies, and the gradual ramp-up of several new products [1][2]. - The company is expected to continue its rapid growth in 2025, driven by the launch of new products and the increasing demand for automotive-grade chips [3][4]. Summary by Sections Financial Performance - In 2Q25, the company reported revenue of RMB 141 million, a year-over-year increase of 71.39% and a quarter-over-quarter increase of 73.74% [1]. - The gross margin improved to 43.98% in 2Q25, reflecting a quarter-over-quarter increase of 3.24 percentage points [1][2]. - The company’s inventory stood at RMB 137 million at the end of 2Q25, with inventory turnover days decreasing to 186 days [2]. Product Development - The company has successfully launched several new products, including 2.5G PHY chips and various switching chips, contributing significantly to revenue growth [2][3]. - The automotive-grade chips, including 100M and 1G PHY chips, have seen rapid growth, with revenues reaching RMB 14 million, a year-over-year increase of 215.48% [2]. - The company plans to introduce a single-port 10G PHY chip by the end of 2025 to expand into high-end application markets [3]. Market Outlook - The company is expected to maintain high revenue growth in 2025, with revenue forecasts of RMB 562 million, RMB 830 million, and RMB 1.215 billion for 2025, 2026, and 2027, respectively [4][10]. - The automotive sector's demand for intelligent and connected products is anticipated to drive the growth of automotive-grade products in the medium to long term [3].

今日早参 2025 年 9 月 02 日 易峘 首席宏观经济学家 邮箱：evayi@htsc.com 易峘 首席宏观经济学家 邮箱：evayi@htsc.com 今日热点 宏观：人民币加速升值，流动性保持宽松 偏低基数和极端天气扰动退坡下，8 月经济高频指标同比稳健；地产成交边 际企稳，部分可能受北京上海地产政策优化和潜在的财富效应提振；居民暑 期出行景气度较高，但以旧换新补贴对汽车消费的支撑边际退坡；外需方 面，8 月港口高频指标显示出口同比或较 7 月放缓。出行及消费方面，7 月 1 日-8 月 23 日全国铁路累计发送旅客数同比+6.4%，8 月国内/国际航班数同比 走高 0.9%/5.3%；8 月 1-24 日，乘用车日均零售销量同比较 7 月的 7%放缓 至 3%。出口方面，高频指标显示 8 月出口同比增速或较 7 月有所放缓。制 造业开工维持韧性：8 月焦化/高炉开工率高于去年同期 3/4.6 个百分点，水 泥开工率同比回落 7.3 个百分点，建筑钢材成交量亦低于去年同期 10.8%。 地产方面，8 月 1-30 日，44 城新房/22 城二手房成交面积同比增速较 7 月的 -19.8%/-6.1 ...

证券研究报告 商汤-W (20 HK) 港股通 经营质量大幅改善，"1+X"成效显著 公司坚定实施"1+X"战略，成效显著，连续三个半年度实现亏损额同比下 降。25H1 公司销售费用和管理费用同比分别下降 17.3%/18.8%，研发费用 同比增加 12%，主要系模型训练微调所需的算力成本增加所致。经营性现 金流出大幅收窄至 6.40 亿元（24H1 为流出 35.24 亿元），主要得益于应收 账款回收加强及库存管理优化，25H1 公司贸易应收回款 31.59 亿元， yoy+95.5%，销售与交付效率显著提升。截至 25 年 6 月 30 日，公司现金 储备为 131.58 亿元，资金充裕。上半年公司毛利率为 38.5%，yoy- 5.6pct， 主要因客户需求增加导致硬件及 AIDC 相关成本上升。 "差异化算力+融合模型+应用生态"构筑商汤三大竞争优势 1）算力：根据中报，截至 25 年 8 月，公司总算力增长至 25000P，在国产 芯片异构混调上实现约 5000 卡规模月级稳定运行，集群利用率约 80%，异 构训练效率达同构约 95%；2）模型：7 月发布的日日新 6.5 成为国内首个 实现图文交错 ...